Sunshine Biopharma, Inc. (SBFM)

Market Cap	4.50M -30.9%
Revenue (ttm)	35.35M -2.7%
Net Income	-5.83M
EPS	-8.20
Shares Out	3.88M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	102,643
Open	1.150
Previous Close	1.160
Day's Range	1.140 - 1.170
52-Week Range	1.030 - 24.300
Beta	1.31
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About SBFM

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurin...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 50
• Stock Exchange: NASDAQ
• Ticker Symbol: SBFM
• Website: https://sunshinebiopharma.com

Financial Performance

In 2025, Sunshine Biopharma's revenue was $36.31 million, an increase of 4.11% compared to the previous year's $34.87 million. Losses were -$5.98 million, 16.4% more than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 22, 2026

Data Sources Report a data error